Women with mild hypertensive disease who undergo induction of labor at 37 weeks or more have a lower risk of poor outcome.
Women experiencing mild hypertensive disease during pregnancy who undergo induction of labor at 37 weeks' gestation or beyond are at a 29% lower risk of a poor outcome, according to a study published online August 4 in the The Lancet.
Corine M. Koopmans, MD, of University Medical Centre in Groningen, Netherlands, and colleagues randomized 756 patients with gestational hypertension or mild preeclampsia to undergo either induction of labor or expectant monitoring. Women were between 36 and 41 weeks' gestation.
The investigators found that maternal outcomes were improved with the induction of labor. A poor maternal outcome was observed in significantly fewer patients randomized to induction of labor compared with expectant monitoring (31% vs. 44%). There was no significant difference in the number of cesarean sections performed in each group, and adverse neonatal outcomes did not differ.
Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; Early Online Publication, 4 August 2009. doi:10.1016/S0140-6736(09)60736-4.
Adverse maternal outcomes after uterine conservation in placenta accreta spectrum
May 9th 2024A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.
Read More
Barriers in seeking pelvic floor disorder treatment among ethnic minorities
May 8th 2024A recent shed light on how ethnic minority groups perceive pelvic floor disorders, highlighting barriers to treatment seeking and the importance of raising awareness about available treatment options.
Read More
Variations found in testosterone therapy for women with HSDD
May 7th 2024Dive into the intricate landscape of testosterone therapy prescriptions among women with hypoactive sexual desire disorder, revealing diverse patterns in duration, administration routes, and estrogen co-administration.
Read More